At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 73 enrolled
Drug / intervention
Bomedemstatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)·interventional·Posted Feb 5, 2020·Updated May 4, 2026
In Brief
A Phase 2 clinical trial evaluating Bomedemstat for Essential Thrombocythemia. Completed, enrolled 73 participants across 26 sites in 7 countries.
Detailed Summary
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia. This study investigates the following: * The safety and tolerability of Bomedemstat * The pharmacodynamic effect of Bomedemstat
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Thrombocythemia
CountriesAustralia, Germany, Hong Kong, Italy, New Zealand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartSep 2020
Primary CompletionMar 2023
TodayJul 2026
First PostedFeb 5, 2020
Enrollment StartSep 8, 2020
Primary CompletionMar 23, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.4 years ago
Interventions
Bomedemstatdrug
Oral administration